A new insight on the effects of Schiff Base Iron (III) complexes in breast cancer cells for clinical radiotherapy.

Purpose: Breast cancer is a significant global health concern, and researchers strive to enhance radiotherapy outcomes while minimizing the side effects. Schiff Base Iron (III) Complexes are one of the prospective elements that can be used as radiosensitizer or radioprotective agents in cancer radiotherapy. This study investigates the potential effects of Schiff base (ligand 2; L) with Fe(III) in MCF-7 breast cancer cells under clinical radiotherapy treatment.

Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy.

Purpose: Chemotherapy has been used in conjunction with radiation therapy to improve the treatment outcomes of cancers. Cisplatin (Cis) is a standard treatment that has been used as a chemotherapeutic drug in medical settings. However, the possibility of complications constrains the treatment due to the exposure of healthy organs to unnecessary radiation and the drugs' toxicities.

Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams.

Purpose: This study aimed to quantify synergetic effects induced by bismuth oxide nanoparticles (BiONPs), cisplatin (Cis) and baicalein-rich fraction (BRF) natural-based agent on the reactive oxygen species (ROS) generation and radiosensitization effects under irradiation of clinical radiotherapy beams of photon, electron and HDR-brachytherapy. The combined therapeutic responses of each compound and clinical radiotherapy beam were evaluated on breast cancer and normal fibroblast cell line.

Methods: In this study, individual BiONPs, Cis, and BRF, as well as combinations of BiONPs-Cis (BC), BiONPs-BRF (BB) and BiONPs-Cis-BRF (BCB) were treated to the cells before irradiation using HDR brachytherapy with 0.

Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy.

Purpose: The aim of this study was to investigate the potential of the synergetic triple therapeutic combination encompassing bismuth oxide nanoparticles (BiONPs), cisplatin (Cis), and high dose rate (HDR) brachytherapy with Ir-192 source in breast cancer and normal fibroblast cell line.

Methods: In vitro models of breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblast cell line (NIH/3T3) were employed. Cellular localization and cytotoxicity studies were conducted prior to inspection on the radiosensitization effects and generation of reactive oxygen species (ROS) on three proposed radiosensitizers: BiONPs, Cis, and BiONPs-Cis combination (BC).

Effect of scanning parameters on dose-response of radiochromic films irradiated with photon and electron beams.

Proper dosimetry settings are crucial in radiotherapy to ensure accurate radiation dose delivery. This work evaluated scanning parameters as affecting factors in reading the dose-response of EBT2 and EBT3 radiochromic films (RCFs) irradiated with clinical photon and electron beams. The RCFs were digitised using Epson Expression 10000XL flatbed scanner and image analyses of net optical density () were conducted using five scanning parameters i.